Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19003866 | COMPOSITIONS CONTAINING SHORT-CHAIN FATTY ACID, METHODS OF USE, AND METHODS OF MAKING THEREOF | December 2024 | August 2025 | Allow | 7 | 1 | 0 | No | No |
| 18651454 | COMPOSITIONS CONTAINING SHORT-CHAIN FATTY ACID, METHODS OF USE, AND METHODS OF MAKING THEREOF | April 2024 | November 2024 | Allow | 7 | 2 | 0 | Yes | No |
| 18600301 | TREATING SAR-COV-2 RELATED HEALTH PROBLEMS | March 2024 | May 2025 | Abandon | 14 | 1 | 0 | No | No |
| 18533052 | WOUND DRESSING BASED ON POLYMERIC MIXTURE OF CELLULOSE ACETATE AND HYALURONIC ACID EMBEDDED WITH COPPER OXIDE AND MAGNESIUM OXIDE NANOPARTICLES | December 2023 | December 2024 | Allow | 12 | 2 | 0 | No | No |
| 18288896 | PHARMACEUTICAL COMPOSITION FOR PREVENTING, ALLEVIATING, OR TREATING CANCER, CONTAINING 2,6-DICHLORO-4-(4-(4-HYDROXYCYCLOHEXYLAMINO)-7H-PYRROLO[2,3-D]PYRIMIDIN-5-YL)PHENOL AS ACTIVE INGREDIENT | October 2023 | January 2026 | Allow | 27 | 0 | 0 | No | No |
| 18552761 | BIVALENT LIGANDS TO UNDERSTAND DIMERIZATION OF THE MU OPIOID RECEPTOR AND THE CHEMOKINE RECEPTOR CCR5 IN NEUROLOGICAL DISORDERS | September 2023 | January 2026 | Allow | 28 | 0 | 0 | No | No |
| 18550342 | ANTIBACTERIAL COMPOUNDS | September 2023 | January 2026 | Allow | 29 | 0 | 0 | Yes | No |
| 18244012 | WOUND DRESSING BASED ON POLYMERIC MIXTURE OF CELLULOSE ACETATE AND HYALURONIC ACID EMBEDDED WITH COPPER OXIDE AND MAGNESIUM OXIDE NANOPARTICLES | September 2023 | November 2024 | Allow | 14 | 3 | 1 | Yes | No |
| 18547513 | NEW-TYPE BENZAZEPINE FUSED RING DERIVATIVE | August 2023 | December 2025 | Allow | 28 | 0 | 0 | No | No |
| 18264298 | BENZOFURAN COMPOUNDS AS STING AGONISTS | August 2023 | February 2026 | Allow | 31 | 1 | 0 | No | No |
| 18270005 | CANCER TREATMENT COMPOSITION AND METHOD | June 2023 | March 2026 | Allow | 33 | 1 | 0 | No | No |
| 18256980 | FUSED [7,5] BICYCLIC PYRAZOLE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF HERPESVIRUSES | June 2023 | November 2025 | Allow | 29 | 0 | 0 | No | No |
| 18134378 | SUBSTITUTED PYRAZOLO PIPERIDINE CARBOXYLIC ACIDS | April 2023 | June 2024 | Allow | 14 | 2 | 0 | Yes | No |
| 18030702 | BENZO[H]QUINAZOLIN-4-AMINE AND THIENO[3,2-H]QUINAZOLIN-4-AMINE DERIVATIVES FOR THE TREATMENT OF CANCER | April 2023 | November 2025 | Allow | 31 | 0 | 0 | No | No |
| 18123128 | LOW-GRADE INFLAMMATION COMPOSITIONS | March 2023 | July 2025 | Allow | 28 | 3 | 0 | No | No |
| 18024290 | METHODS TO TREAT INFLAMMATORY BOWEL DISEASE | March 2023 | March 2026 | Abandon | 48 | 1 | 0 | No | No |
| 18115995 | Polymorphs of Crystalline Forms of 3,10-dimethoxy-5,8,13,13a-tetrahydro-6H-isoquinolino[3,2-a]isoquinolin-9-yl 3-fluorobenzenesulfonate and Salts Thereof | March 2023 | March 2026 | Abandon | 37 | 1 | 0 | No | No |
| 18042091 | PYRIMIDINONE COMPOUNDS AND USES THEREOF | February 2023 | January 2026 | Allow | 35 | 1 | 0 | No | No |
| 18040443 | LONG ACTING ANTICANCER COMPOSITIONS | February 2023 | January 2026 | Allow | 36 | 1 | 0 | No | No |
| 18067497 | TREATMENT OF MGMT DEFICIENT CANCER WITH 2-FLUOROETHYL-SUBSTITUTED NITROSOUREAS AND OTHER COMPOUNDS | December 2022 | July 2025 | Abandon | 31 | 2 | 1 | No | No |
| 18082353 | LEVOCETIRIZINE AND MONTELUKAST IN THE TREATMENT OF CORONAVIRUS DISEASE AND SYMPTOMS THEREOF | December 2022 | January 2025 | Abandon | 25 | 2 | 0 | No | No |
| 18073886 | GCN2 AND PERK KINASE INHIBITORS AND METHODS OF USE THEREOF | December 2022 | November 2025 | Allow | 35 | 3 | 0 | No | No |
| 17999514 | 3-((1H-PYRAZOL-4-YL)METHYL)-6'-(PHENYL)-2H-(1,2'-BIPYRIDIN)-2-ONE DERIVATIVES AND RELATED COMPOUNDS AS GPR139 ANTAGONISTS FOR USE IN A METHOD OF TREATMENT OF E.G. DEPRESSION | November 2022 | October 2025 | Allow | 35 | 1 | 0 | No | No |
| 17990658 | BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR | November 2022 | March 2026 | Abandon | 40 | 1 | 0 | No | No |
| 17985622 | METHOD FOR ALLEVIATING CHRONIC LIVER DISEASE USING ROSOXACIN | November 2022 | March 2024 | Allow | 16 | 1 | 0 | No | No |
| 18052838 | 4-Amino Pyrimidine Compounds for the Treatment of Cancer | November 2022 | May 2025 | Allow | 40 | 3 | 0 | No | No |
| 17974000 | METHODS FOR TREATING VIRAL INFECTIONS, ORGAN INJURY, AND RELATED CONDITIONS | October 2022 | February 2025 | Abandon | 28 | 2 | 0 | No | No |
| 18048773 | METHODS AND COMPOSITIONS FOR TREATING CHRONIC INFLAMMATORY INJURY, METAPLASIA, DYSPLASIA AND CANCERS OF EPITHELIAL TISSUES | October 2022 | October 2025 | Abandon | 36 | 2 | 1 | No | No |
| 17969836 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF TOXIC GAS EXPOSURE | October 2022 | July 2024 | Abandon | 21 | 1 | 1 | No | No |
| 17960039 | AROMATIC IMMUNOREGULATORY COMPOUNDS FOR TREATMENT OF INFLAMMATORY DISEASES | October 2022 | July 2024 | Allow | 22 | 2 | 0 | Yes | No |
| 17913206 | SUBSTITUTED OXOISOINDOLINE COMPOUNDS FOR THE TREATMENT OF CANCER | September 2022 | October 2025 | Allow | 37 | 1 | 0 | Yes | No |
| 17889244 | IRON SUPPLEMENT COMPOSITIONS AND METHODS OF USE THEREOF | August 2022 | May 2025 | Abandon | 33 | 3 | 1 | No | No |
| 17798017 | MYC INHIBITORS AND USES THEREOF | August 2022 | October 2025 | Allow | 38 | 1 | 0 | No | No |
| 17795349 | ANTIMALARIAL AGENTS | July 2022 | February 2026 | Allow | 43 | 3 | 0 | No | No |
| 17759236 | Chemical Process for the Preparation of Herbicidal Pyridazine Compounds | July 2022 | January 2026 | Abandon | 42 | 1 | 0 | No | No |
| 17792193 | PROCESSES FOR THE PREPARATION OF GLASDEGIB AND SALT THEREOF AND SOLID STATE FORMS OF GLASDEGIB MALEATE AND PROCESS FOR PREPARATION THEREOF | July 2022 | March 2026 | Allow | 44 | 1 | 1 | No | No |
| 17758693 | PYRAZOLYLPYRIMIDINES AND USE THEREOF | July 2022 | August 2025 | Abandon | 37 | 1 | 0 | No | No |
| 17757979 | UTIDELONE SEMI-HYDRATED SINGLE CRYSTAL AND PREPARATION METHOD THEREFOR AND USE THEREOF | June 2022 | March 2026 | Allow | 45 | 1 | 0 | Yes | No |
| 17787135 | PRMT5 INHIBITORS | June 2022 | August 2025 | Allow | 38 | 1 | 0 | No | No |
| 17807094 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF IRAK-4 | June 2022 | March 2026 | Abandon | 45 | 0 | 1 | No | No |
| 17785205 | Deuterated analogues of selenophenochromenes, synthesis thereof, and methods of using same agents | June 2022 | January 2026 | Allow | 43 | 2 | 0 | No | No |
| 17782530 | COMBINATION OF AN AZETIDINE LPA1 RECEPTOR ANTAGONIST WITH PIRFENIDONE AND/OR NINTEDANIB FOR USE IN THE TREATMENT OF FIBROTIC DISEASES | June 2022 | September 2025 | Allow | 40 | 1 | 0 | No | No |
| 17664882 | REGIMENS FOR TREATING HIV INFECTIONS AND AIDS | May 2022 | December 2025 | Abandon | 43 | 3 | 0 | No | Yes |
| 17755414 | CRYSTALLINE FORMS OF ENTRECTINIB | April 2022 | July 2025 | Abandon | 39 | 1 | 0 | No | No |
| 17755435 | THE USE OF A SPLICING MODULATOR FOR A TREATMENT SLOWING PROGRESSION OF HUNTINGTON'S DISEASE | April 2022 | October 2025 | Abandon | 42 | 1 | 0 | No | No |
| 17772192 | ALK INHIBITORS FOR TREATMENT OF ALK-NEGATIVE CANCER AND PLASMA CELL-MEDIATED DISEASES | April 2022 | August 2025 | Allow | 40 | 1 | 0 | No | No |
| 17772099 | METHODS FOR TREATING LEUKEMIA AND USE OF A LEUKEMIC STEM CELL SIGNATURE TO PREDICT CLINICAL SENSITIVITY TO THERAPIES | April 2022 | August 2025 | Abandon | 39 | 1 | 0 | No | No |
| 17770435 | USE OF CANNABIDIOL PREPARATIONS IN THE TREATMENT OF FRAGILE X SYNDROME | April 2022 | November 2025 | Abandon | 43 | 1 | 0 | No | No |
| 17770436 | CANNABIDIVARIN PREPARATIONS FOR USE AS A MEDICAMENT | April 2022 | November 2025 | Abandon | 43 | 1 | 0 | No | No |
| 17716965 | CRYSTALLINE SOLVATED FORMS OF N-(4-(1-(2,6-DIFLUOROBENZYL)-5- ((DIMETHYLAMINO)METHYL)-3-(6-METHOXY-3-PYRIDAZINYL)-2,4-DIOXO-1,2,3,4- TETRAHYDROTHIENO[2,3-D]PYRIMIDIN-6-YL)PHENYL)-N'-METHOXYUREA | April 2022 | February 2026 | Allow | 46 | 2 | 0 | No | No |
| 17763205 | CONTROLLED RELEASE INJECTABLE ONDANSETRON FORMULATIONS | March 2022 | April 2025 | Allow | 37 | 1 | 0 | No | No |
| 17667410 | SUBSTITUTED PYRAZOLO PIPERIDINE CARBOXYLIC ACIDS | February 2022 | August 2025 | Allow | 42 | 2 | 0 | No | No |
| 17631028 | SOLID STATE FORMS OF RISDIPLAM AND PROCESS FOR PREPARATION THEREOF | January 2022 | September 2025 | Allow | 44 | 0 | 1 | Yes | No |
| 17626709 | PHARMACEUTICAL COMPOSITION FOR SUBCUTANEOUS ADMINISTRATION | January 2022 | November 2025 | Allow | 46 | 2 | 0 | Yes | No |
| 17567081 | METHOD, SYSTEM, FORMULATION AND KIT FOR THE TREATMENT OF ONYCHOMYCOSIS | December 2021 | January 2025 | Abandon | 37 | 2 | 0 | No | No |
| 17555736 | TREATING SAR-COV-2 RELATED HEALTH PROBLEMS | December 2021 | October 2022 | Allow | 10 | 3 | 0 | Yes | No |
| 17548914 | CHEMICAL INHIBITION OF THE E3 LIGASE SUBUNIT FBXO7 CONFERS NEUROPROTECTION AND ANTI-INFLAMMATORY ACTIVITY BY STABILIZING MITOCHONDRIA | December 2021 | April 2025 | Allow | 40 | 1 | 0 | No | No |
| 17618687 | PROCESS FOR THE PREPARATION OF 2-FLUOROADENINE | December 2021 | April 2025 | Allow | 40 | 1 | 0 | No | No |
| 17544641 | COMBINATIONS OF INHIBITORS OF IRAK4 WITH INHIBITORS OF BTK | December 2021 | May 2025 | Abandon | 41 | 1 | 0 | No | No |
| 17543245 | COMPOSITIONS AND METHODS FOR CANCER THERAPY | December 2021 | June 2025 | Abandon | 42 | 1 | 0 | No | No |
| 17612951 | (R)-3-(3-CHLORO-5-FLUORO-2-((4-(1H-PYRAZOL-1-YL)-2-METHYLQUINOLIN-8-YLOXY)METHYL)PHENYL)MORPHOLINE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ (BK) B2 RECEPTOR ANTAGONIST FOR TREATING SKIN DISEASES | November 2021 | April 2025 | Allow | 41 | 1 | 0 | No | No |
| 17612519 | COMPOSITION AND USE THEREOF FOR THE TREATMENT OF CUTANEOUS MASTOCYTOSIS | November 2021 | May 2025 | Abandon | 42 | 1 | 0 | No | No |
| 17606212 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING TREATMENT-RESISTANT CANCER | October 2021 | March 2025 | Abandon | 41 | 1 | 0 | No | No |
| 17605990 | 4H-PYRROLO[3,2-C]PYRIDIN-4-ONE DERIVATIVES | October 2021 | April 2025 | Allow | 42 | 1 | 0 | Yes | No |
| 17603553 | CD73 INHIBITORS | October 2021 | April 2025 | Abandon | 42 | 1 | 0 | No | No |
| 17603091 | COMPOUNDS AND METHODS FOR TREATING INFLAMMATORY DISORDERS | October 2021 | April 2025 | Allow | 42 | 1 | 0 | No | No |
| 17440396 | STABILISATION AND CONTROLLED-RELEASE SYSTEMS FOR MEDICAMENTS UNSTABLE ON STERILISATION | September 2021 | September 2025 | Allow | 48 | 2 | 0 | No | No |
| 17437761 | THERAPEUTIC AGENT FOR CORNEAL DISEASES | September 2021 | February 2025 | Abandon | 42 | 1 | 0 | No | No |
| 17437379 | NEW TECHNOLOGY TO CONJUGATE THE TACCALONOLIDE MICROTUBULE STABILIZERS WITH LINKERS/PAYLOADS | September 2021 | October 2025 | Abandon | 49 | 0 | 1 | No | No |
| 17446063 | Pantoprazole Compositions and Methods | August 2021 | May 2024 | Allow | 33 | 1 | 0 | No | No |
| 17433706 | METHOD FOR TREATING HAIR AND SCALP | August 2021 | January 2026 | Allow | 53 | 4 | 0 | No | No |
| 17433572 | HETEROCYCLIC COMPOUND AND AGRICULTURAL OR HORTICULTURAL FUNGICIDE | August 2021 | February 2025 | Abandon | 42 | 1 | 0 | No | No |
| 17402564 | CHK1/2 INHIBITORS FOR USE IN THE TREATMENT OF NEUROBLASTOMAS AND/OR SOFT TISSUE SARCOMAS | August 2021 | October 2025 | Allow | 50 | 3 | 0 | No | No |
| 17400468 | Synthesis of small molecules inspired by Phomoxanthone A | August 2021 | February 2026 | Allow | 54 | 2 | 1 | No | No |
| 17394572 | NEW ANTIBACTERIAL COMPOUND ISOLATED FROM PSILOXYLON MAURITIANUM AND ITS DERIVATIVES | August 2021 | October 2024 | Allow | 38 | 2 | 1 | Yes | No |
| 17428406 | NOVEL AZOBENZENE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE FOR THERAPEUTIC TREATMENT ASSOCIATED WITH IONIZING RADIATIONS | August 2021 | March 2025 | Allow | 43 | 2 | 0 | Yes | No |
| 17421247 | ANTIMICROBIAL COMPOUNDS AND COMPOSITIONS COMPRISING SAME | July 2021 | September 2025 | Abandon | 51 | 3 | 0 | No | No |
| 17421299 | METHODS OF TREATING CONDITIONS RELATED TO THE S1P1 RECEPTOR | July 2021 | September 2025 | Abandon | 50 | 3 | 0 | No | No |
| 17368290 | PHARMACEUTICAL COMPOUNDS | July 2021 | August 2025 | Allow | 50 | 2 | 0 | No | No |
| 17418686 | COMPOSITION FOR SUPRESSING SECRETION OF EXTRACELLULAR VESICLES | June 2021 | June 2025 | Abandon | 48 | 1 | 0 | No | No |
| 17418451 | A METHOD FOR TREATING SWI/SNF COMPLEX-DEFICIENT CANCERS COMPRISING GLUTATHIONE (GSH) METABOLIC PATHWAY INHIBITOR | June 2021 | November 2024 | Abandon | 41 | 1 | 0 | No | No |
| 17358002 | AMINOQUINAZOLINONE AND AMINOISOQUINOLINONE DERIVATIVES AND APPLICATION THEREOF | June 2021 | May 2025 | Allow | 47 | 1 | 1 | No | No |
| 17359182 | METHOD FOR TREATING MOVEMENT DISORDERS WITH BEFIRADOL | June 2021 | July 2025 | Allow | 49 | 3 | 0 | Yes | No |
| 17416175 | NEW SALICYLIC ACID DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, COMPOSITION THEREOF AND METHOD OF USE THEREOF | June 2021 | September 2024 | Abandon | 39 | 1 | 0 | No | No |
| 17415496 | 1,3,4-OXADIAZOLES AND THEIR DERIVATIVES AS NEW ANTIFUNGAL AGENTS | June 2021 | February 2025 | Abandon | 44 | 1 | 0 | No | No |
| 17311239 | VIBEGRON FOR THE TREATMENT OF OVERACTIVE BLADDER SYMPTOMS | June 2021 | March 2025 | Allow | 45 | 2 | 0 | Yes | No |
| 17299361 | METHODS FOR TREATING CANCER IN MODELS HARBORING ESR1 MUTATIONS | June 2021 | June 2025 | Abandon | 49 | 2 | 0 | No | No |
| 17296076 | USE OF CANNABINOLIDS IN THE TREATMENT OF EPILEPSY | May 2021 | July 2025 | Abandon | 50 | 2 | 0 | No | No |
| 17293751 | PROPHYLACTIC OR THERAPEUTIC AGENT AND MEDICINAL COMPOSITION FOR IL-31-MEDIATED DISEASE | May 2021 | February 2025 | Abandon | 45 | 0 | 1 | No | No |
| 17309200 | CANNABINOID COMPOSITIONS WITH HIGH SOLUBILITY AND BIOAVAILABILITY | May 2021 | January 2025 | Abandon | 44 | 2 | 0 | No | No |
| 17245828 | COMPOUNDS AND METHODS FOR PREVENTION AND TREATMENT OF CORONAVIRUS INFECTIONS | April 2021 | July 2025 | Allow | 50 | 2 | 1 | No | No |
| 17244184 | GRANULATED PRODUCT CONTAINING ANTITUMOR AGENT | April 2021 | November 2024 | Abandon | 43 | 1 | 0 | No | No |
| 17288942 | COMPOSITIONS COMPRISING CANNABINOIDS FOR USE IN THE TREATMENT OF BIOFILM AND CONDITIONS ASSOCIATED WITH MICROBIAL, FUNGAL, BACTERIAL INFECTIONS | April 2021 | February 2026 | Abandon | 58 | 3 | 0 | No | No |
| 17235120 | ANTIVIRAL 1,3-DI-OXO-INDENE COMPOUNDS | April 2021 | August 2024 | Allow | 40 | 3 | 1 | Yes | No |
| 17233668 | INDOLINONE DERIVATIVES AS INHIBITORS OF MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE | April 2021 | May 2025 | Abandon | 49 | 2 | 0 | No | No |
| 17284323 | Compositions Comprising Guaifenesin and Flavour Compounds Containing an Isovanillyl Group | April 2021 | June 2025 | Allow | 50 | 4 | 0 | No | No |
| 17284112 | ANTICANCER ROCAGLAMIDE DERIVATIVES | April 2021 | February 2025 | Allow | 47 | 3 | 0 | No | No |
| 17284306 | USNIC ACID DERIVATIVE HAVING TSLP SECRETION INHIBITORY ABILITY AND USE THEREOF | April 2021 | July 2024 | Allow | 39 | 1 | 0 | Yes | No |
| 17284380 | DISINFECTING COMPOSITION FOR TOPICAL USE | April 2021 | September 2024 | Abandon | 41 | 1 | 0 | No | No |
| 17283767 | DIHYDROIMIDAZOPYRAZINONE COMPOUND, COMPOSITION INCLUDING SAME, AND USE THEREOF | April 2021 | February 2025 | Abandon | 46 | 2 | 0 | No | No |
No appeal data available for this record. This may indicate that no appeals have been filed or decided for applications in this dataset.
Examiner ROBINSON, MIKHAIL O'DONNEL works in Art Unit 1627 and has examined 57 patent applications in our dataset. With an allowance rate of 52.6%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 45 months.
Examiner ROBINSON, MIKHAIL O'DONNEL's allowance rate of 52.6% places them in the 14% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by ROBINSON, MIKHAIL O'DONNEL receive 1.84 office actions before reaching final disposition. This places the examiner in the 43% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by ROBINSON, MIKHAIL O'DONNEL is 45 months. This places the examiner in the 12% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +56.2% benefit to allowance rate for applications examined by ROBINSON, MIKHAIL O'DONNEL. This interview benefit is in the 95% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 30.4% of applications are subsequently allowed. This success rate is in the 60% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.
This examiner enters after-final amendments leading to allowance in 33.3% of cases where such amendments are filed. This entry rate is in the 49% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants file petitions regarding this examiner's actions, 72.7% are granted (fully or in part). This grant rate is in the 79% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 1% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 13.3% of allowed cases (in the 91% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.